1. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents: PROLONGED SURVIVAL OBSERVED IN 133 MDS PATIENTS TREATED WITH ORAL DECITABINE/CEDAZURIDINE. (September 2021) Authors: Savona, M.; Mccloskey, J.; Griffiths, E.; Yee, K.; Al-Kali, A.; Zeidan, A.M.; Deeg, H.J.; Patel, P.; Sabloff, M.; Keating, M.-M.; Dao, K.-H.; Zhu, N.; Gabrail, N.; Fazal, S.; Maly, J.; Odenike, O.; Kantarjian, H.; Dezern, A.; O'Connell, C.; Roboz, G. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY. (23rd June 2022) Authors: Khadadah, F.; Turkina, A. G.; Lomaia, E.; Morozova, E. V.; Shukhov, O. A.; Petrova, A.; Chitanava, T.; Vlasova, J. J.; Kuzmina, E.; Nemchenko, I.; Chelysheva, E. Y.; Bykova, A.; Gurianova, M.; Xenocostas, A.; Busque, L.; Jamani, K.; Cerquozzi, S.; Kuruvilla, P.; Kaedbey, R.; Leber, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB. (23rd June 2022) Authors: Kim, D.; Atenafu, E.; Forrest, D.; Bence-Bruckler, I.; Savoie, L.; Keating, M.-M.; Busque, L.; Delage, R.; Xenocostas, A.; Liew, E.; Laneuville, P.; Paulson, K.; Stockley, T.; Lipton, J.; Leber, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT. (23rd June 2022) Authors: Busque, L.; Harnois, M.; Szuber, N.; Delage, R.; Mollica, L.; Olney, H.; Laneuville, P.; Sirhan, S.; Cournoyer, G.; Chamakhi, I.; Lalancette, M.; Talbot, D.; Éthier, V.; Desjardins, P.; Assouline, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. (May 2023) Authors: Savona, M.; Mccloskey, J.; Griffiths, E.; Yee, K.; Zeidan, A.; Al-Kali, A.; Deeg, H.J.; Patel, P.; Sabloff, M.; Keating, M.-M.; Zhu, N.; Gabrail, N.; Fazal, S.; Maly, J.; Odenike, O.; Kantarjian, H.; Dezern, A.; O'Connell, C.; Roboz, G.; Busque, L. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗